{"entity":{"id":"nct05689853","kind":"trial","name":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AK119 in advanced solid tumours, run by Akeso, now recruiting.","summary":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05689853 by Akeso, with 87 participants planned, started 2023-04-14 and due to reach its primary completion in 2026-12. Interventions recorded: AK119 and AK112.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05689853","url":"https://clinicaltrials.gov/study/NCT05689853"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ak119"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05689853","phase":"1/2","setting":"An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors","sponsor":"Akeso","enrolled":87,"outcomes":[]},"route":"/trials/nct05689853/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ak119","kind":"drug","name":"AK119","route":"/drugs/ak119/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}